Printer Friendly

ViiV Healthcare seeks US FDA approval for two-drug HIV treatment.

M2 EQUITYBITES-May 1, 2019-ViiV Healthcare seeks US FDA approval for two-drug HIV treatment

(C)2019 M2 COMMUNICATIONS http://www.m2.com

United Kingdom-based ViiV Healthcare is seeking approval from the US Food and Drug Administration (FDA) for the investigational, monthly, injectable, two-drug regimen of cabotegravir and rilpivirine to treat HIV, it was reported yesterday.

The company has submitted a new drug application to the US FDA for the two-drug regimen to treat HIV-1 infection in adults whose viral load is suppressed and who are not resistant to cabotegravir or rilpivirine. Cabotegravir, which is ViiV Healthcare's investigational integrase inhibitor, is not approved by regulatory authorities anywhere in the world. It is being developed for the treatment and prevention of HIV.

The application was submitted based on data from the global ATLAS (Antiretroviral Therapy as Long-Acting Suppression) and FLAIR (First Long-Acting Injectable Regimen) pivotal phase III studies, which assessed more than 1,100 patients from 16 countries. The studies indicated that the combination of cabotegravir and rilpivirine, injected monthly, was as effective as a standard of care, daily, oral, three-drug regimen in maintaining viral suppression throughout the 48-week study period, according to the company.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:May 1, 2019
Words:203
Previous Article:US FDA grants fast track designation to Finch Therapeutics' Full-Spectrum Microbiota therapy.
Next Article:European Medicines Agency's committee adopts positive opinion for AstraZeneca and Merck's LYNPARZA for ovarian cancer.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |